Literature DB >> 1184961

Niridazole, a potent long-acting suppressant of cellular hypersensitivity. III. Minimal suppression of antibody responses.

R P Pelley, R J Pelley, A B Stavitsky, A A Mahmoud, K S Warren.   

Abstract

Niridazole, an anthelminthic drug, has been shown to be a potent long-acting suppressant of cell-mediated immune responses both in man and in experimental animals. In the present study the effect of niridazole on the magnitude and kinetics of the primary and secondary antibody responses of mice to sheep erythrocytes, human serum albumin, and keyhold limpet hemocyanin was investigated. The therapeutic dose of niridazole for murine schistosomiasis moderately and transiently inhibited the primary antibody response to these antigens, but had no effect on ongoing antibody production against keyhole limpet hemocyanin or on secondary responses to any of the antigens. Single doses of niridazole (which suppress cell-mediated immune responses) had no effect whatsoever on the most strongly inhibited of the primary antibody responses, that to alum-precipitated polymerized human serum albumin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184961

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  Listeriosis in sheep. Experimental listeric infection in sheep treated with various immunosuppressiva.

Authors:  H Grønstøl
Journal:  Acta Vet Scand       Date:  1980       Impact factor: 1.695

2.  Studies on the pathogenesis of experimental autoimmune renal tubulointerstitial disease in guinea-pigs. IV. failure to inhibit mononuclear cell accumulation with niridazole.

Authors:  U H Rudofsky; B Pollara
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

3.  Effect of niridazole in cellular immunity in vivo and in vitro.

Authors:  W Solbach; H Wagner; M Röllinghoff
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

4.  Immunosuppressive properties of sera and urine dialysates from kidney-graft recipients treated with azathioprine, prednisolone, and niridazole.

Authors:  B M Jones; M Bird; P Massey; D Millar; J J Miller; S Reeves; J R Salaman
Journal:  Br Med J       Date:  1977-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.